Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications.
Acute Myeloid Leukemia
Hematopoiesis
Leukemia
Leukemia Stem Cell
Journal
Stem cell reviews and reports
ISSN: 2629-3277
Titre abrégé: Stem Cell Rev Rep
Pays: United States
ID NLM: 101752767
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
21
11
2021
pubmed:
21
1
2022
medline:
27
4
2022
entrez:
20
1
2022
Statut:
ppublish
Résumé
The stem cells of acute myeloid leukemia (AML) are the malignancy initiating cells whose survival ultimately drives growth of these lethal diseases. Here we review leukemia stem cell (LSC) biology, particularly as it relates to the very heterogeneous nature of AML and to its high disease relapse rate. Leukemia ontogeny is presented, and the defining functional and phenotypic features of LSCs are explored. Surface and metabolic phenotypes of these cells are described, particularly those that allow distinction from features of normal hematopoietic stem cells (HSCs). Opportunities for use of this information for improving therapy for this challenging group of diseases is highlighted, and we explore the clinical needs which may be addressed by emerging LSC data. Finally, we discuss current gaps in the scientific understanding of LSCs.
Identifiants
pubmed: 35050458
doi: 10.1007/s12015-021-10308-6
pii: 10.1007/s12015-021-10308-6
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1211-1226Subventions
Organisme : NIH HHS
ID : 2P01CA171983-06A1
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Estey, E. H. (2018). “Acute myeloid leukemia: 2019 update on risk-stratification and management,” (in eng). American Journal of Hematology, 93(10), 1267–1291. https://doi.org/10.1002/ajh.25214
doi: 10.1002/ajh.25214
pubmed: 30328165
Bonnet, D., & Dick, J. E. (1997). “Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell,” (in eng). Nature Medicine, 3(7), 730–737. https://doi.org/10.1038/nm0797-730
doi: 10.1038/nm0797-730
pubmed: 9212098
Sanchez-Aguilera, A., & Mendez-Ferrer, S. (2017). The hematopoietic stem-cell niche in health and leukemia. Cellular and Molecular Life Sciences, 74(4), 579–590. https://doi.org/10.1007/s00018-016-2306-y
doi: 10.1007/s00018-016-2306-y
pubmed: 27436341
Batsivari, A., Grey, W., & Bonnet, D. (2021). Understanding of the crosstalk between normal residual hematopoietic stem cells and the leukemic niche in acute myeloid leukemia. Experimental Hematology, 95, 23–30. https://doi.org/10.1016/j.exphem.2021.01.004
doi: 10.1016/j.exphem.2021.01.004
pubmed: 33497761
Fialkow, P. J. (1979). Clonal origin of human tumors. Annual Review of Medicine, 30, 135–143. https://doi.org/10.1146/annurev.me.30.020179.001031
doi: 10.1146/annurev.me.30.020179.001031
pubmed: 400484
R. G. Wiggans, Jacobson, R. J., Fialkow, P. J., Woolley, 3rd P. V. , Macdonald, J. S., & Schein, P. S. (1978). Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer,. Blood, 52(4), 659–663. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/278630 .
Lapidot, T., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645–648.
doi: 10.1038/367645a0
pubmed: 7509044
Kreso, A., & Dick, J. E. (2014). “Evolution of the cancer stem cell model,” (in eng). Cell Stem Cell, 14(3), 275–291. https://doi.org/10.1016/j.stem.2014.02.006
doi: 10.1016/j.stem.2014.02.006
pubmed: 24607403
Nowell, P. C., & Hungerford, D. A. (1964). Chromosome changes in human leukemia and a tentative assessment of their significance. Annals of the New York Academy of Sciences, 113, 654–662. https://doi.org/10.1111/j.1749-6632.1964.tb40697.x
doi: 10.1111/j.1749-6632.1964.tb40697.x
pubmed: 14120519
Mitelman, F., Nilsson, P. G., Levan, G., & Brandt, L. (1976). Non-random chromosome changes in acute myeloid leukemia. Chromosome banding examination of 30 cases at diagnosis. International Journal of Cancer, 18(1), 31–38. https://doi.org/10.1002/ijc.2910180106
doi: 10.1002/ijc.2910180106
pubmed: 1065619
Arber, D. A., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405. https://doi.org/10.1182/blood-2016-03-643544
doi: 10.1182/blood-2016-03-643544
pubmed: 27069254
Papaemmanuil, E., Dohner, H., & Campbell, P. J. (2016). Genomic Classification in Acute Myeloid Leukemia. New England Journal of Medicine, 375(9), 900–901. https://doi.org/10.1056/NEJMc1608739
doi: 10.1056/NEJMc1608739
pubmed: 27579651
Dohner, H., et al. (2017). Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 129(4), 424–447. https://doi.org/10.1182/blood-2016-08-733196
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Stubbs, M. C., et al. (2008). MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: Development of a model for rapid therapeutic assessment. Leukemia, 22(1), 66–77. https://doi.org/10.1038/sj.leu.2404951
doi: 10.1038/sj.leu.2404951
pubmed: 17851551
Uckelmann, H. J., et al. (2020). Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science, 367(6477), 586–590. https://doi.org/10.1126/science.aax5863
doi: 10.1126/science.aax5863
pubmed: 32001657
pmcid: 7754791
Song, C., et al. (2016). Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia. Leukemia, 30(6), 1436–1440. https://doi.org/10.1038/leu.2015.331
doi: 10.1038/leu.2015.331
pubmed: 26639180
pmcid: 4889471
N. Cancer Genome Atlas Research et al. (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine, 368(22), 2059–2074. https://doi.org/10.1056/NEJMoa1301689 .
Wang, J. C., & Dick, J. E. (2005). “Cancer stem cells: Lessons from leukemia,” (in eng). Trends in Cell Biology, 15(9), 494–501. https://doi.org/10.1016/j.tcb.2005.07.004
doi: 10.1016/j.tcb.2005.07.004
pubmed: 16084092
Majeti, R., Park, C. Y., & Weissman, I. L. (2007). “Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood,” (in eng). Cell Stem Cell, 1(6), 635–645. https://doi.org/10.1016/j.stem.2007.10.001
doi: 10.1016/j.stem.2007.10.001
pubmed: 18371405
pmcid: 2292126
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M., & Sutherland, H. J. (1997). “Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo,” (in eng). Blood, 89(9), 3104–3112.
doi: 10.1182/blood.V89.9.3104
pubmed: 9129012
Miyamoto, T., Weissman, I. L., & Akashi, K. (2000). “AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation,” (in eng). Proc Natl Acad Sci U S A, 97(13), 7521–7526. https://doi.org/10.1073/pnas.97.13.7521
doi: 10.1073/pnas.97.13.7521
pubmed: 10861016
pmcid: 16578
Shlush, L. I., et al. (2014). “Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia,” (in eng). Nature, 506(7488), 328–333. https://doi.org/10.1038/nature13038
doi: 10.1038/nature13038
pubmed: 24522528
pmcid: 4991939
Busque, L., et al. (2012). Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 44(11), 1179–1181. https://doi.org/10.1038/ng.2413
doi: 10.1038/ng.2413
pubmed: 23001125
pmcid: 3483435
Genovese, G., et al. (2014). Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. New England Journal of Medicine, 371(26), 2477–2487. https://doi.org/10.1056/NEJMoa1409405
doi: 10.1056/NEJMoa1409405
pubmed: 25426838
Genovese, G., Jaiswal, S., Ebert, B. L., & McCarroll, S. A. (2015). Clonal hematopoiesis and blood-cancer risk. New England Journal of Medicine, 372(11), 1071–1072. https://doi.org/10.1056/NEJMc1500684
doi: 10.1056/NEJMc1500684
pubmed: 25760361
Kwok, B., et al. (2015). MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood, 126(21), 2355–2361. https://doi.org/10.1182/blood-2015-08-667063
doi: 10.1182/blood-2015-08-667063
pubmed: 26429975
pmcid: 4653764
Buscarlet, M., et al. (2017). DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood, 130(6), 753–762. https://doi.org/10.1182/blood-2017-04-777029
doi: 10.1182/blood-2017-04-777029
pubmed: 28655780
Jaiswal, S., et al. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine, 371(26), 2488–2498. https://doi.org/10.1056/NEJMoa1408617
doi: 10.1056/NEJMoa1408617
pubmed: 25426837
Loberg, M. A., et al. (2019). Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia, 33(7), 1635–1649. https://doi.org/10.1038/s41375-018-0368-6
doi: 10.1038/s41375-018-0368-6
pubmed: 30692594
pmcid: 6609470
Chen, J., et al. (2019). Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nature Medicine, 25(1), 103–110. https://doi.org/10.1038/s41591-018-0267-4
doi: 10.1038/s41591-018-0267-4
pubmed: 30510255
Cleary, A. S., Leonard, T. L., Gestl, S. A., & Gunther, E. J. (2014). Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature, 508(7494), 113–117. https://doi.org/10.1038/nature13187
doi: 10.1038/nature13187
pubmed: 24695311
pmcid: 4050741
Kleppe, M., & Levine, R. L. (2014). Tumor heterogeneity confounds and illuminates: Assessing the implications. Nature Medicine, 20(4), 342–344. https://doi.org/10.1038/nm.3522
doi: 10.1038/nm.3522
pubmed: 24710377
Miles, L. A., et al. (2020). Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature, 587(7834), 477–482. https://doi.org/10.1038/s41586-020-2864-x
doi: 10.1038/s41586-020-2864-x
pubmed: 33116311
pmcid: 7677169
Lapidot, T., et al. (1994). “A cell initiating human acute myeloid leukaemia after transplantation into SCID mice,” (in eng). Nature, 367(6464), 645–648. https://doi.org/10.1038/367645a0
doi: 10.1038/367645a0
pubmed: 7509044
Ishikawa, F., et al. (2005). “Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice,” (in eng). Blood, 106(5), 1565–1573. https://doi.org/10.1182/blood-2005-02-0516
doi: 10.1182/blood-2005-02-0516
pubmed: 15920010
pmcid: 1895228
Barve, A., Casson, L., Krem, M., Wunderlich, M., Mulloy, J. C., & Beverly, L. J. (2018). Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response. Experimental Hematology, 67, 18–31. https://doi.org/10.1016/j.exphem.2018.08.004
doi: 10.1016/j.exphem.2018.08.004
pubmed: 30125602
pmcid: 6200600
Taussig, D. C., et al. (2008). “Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells,” (in eng). Blood, 112(3), 568–575. https://doi.org/10.1182/blood-2007-10-118331
doi: 10.1182/blood-2007-10-118331
pubmed: 18523148
Hope, K. J., Jin, L., & Dick, J. E. (2004). “Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity,” (in eng). Nature Immunology, 5(7), 738–743. https://doi.org/10.1038/ni1080
doi: 10.1038/ni1080
pubmed: 15170211
Thomas, D., & Majeti, R. (2017). “Biology and relevance of human acute myeloid leukemia stem cells,” (in eng). Blood, 129(12), 1577–1585. https://doi.org/10.1182/blood-2016-10-696054
doi: 10.1182/blood-2016-10-696054
pubmed: 28159741
pmcid: 5364335
Ishikawa, F., et al. (2007). “Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region,” (in eng). Nature Biotechnology, 25(11), 1315–1321. https://doi.org/10.1038/nbt1350
doi: 10.1038/nbt1350
pubmed: 17952057
Saito, Y., et al. (2010). “Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML,” (in eng). Nature Biotechnology, 28(3), 275–280. https://doi.org/10.1038/nbt.1607
doi: 10.1038/nbt.1607
pubmed: 20160717
Boyd, A. L., et al. (2018). “Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of Human AML Recurrence,” (in eng). Cancer Cell, 34(3), 483-498.e5. https://doi.org/10.1016/j.ccell.2018.08.007
doi: 10.1016/j.ccell.2018.08.007
pubmed: 30205048
Farge, T., et al. (2017). “Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism,” (in eng). Cancer Discovery, 7(7), 716–735. https://doi.org/10.1158/2159-8290.cd-16-0441
doi: 10.1158/2159-8290.cd-16-0441
pubmed: 28416471
pmcid: 5501738
Griessinger, E., et al. (2014). “A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: A new tool to decipher their chemoresistance and self-renewal mechanisms,” (in eng). Stem Cells Translational Medicine, 3(4), 520–529. https://doi.org/10.5966/sctm.2013-0166
doi: 10.5966/sctm.2013-0166
pubmed: 24493855
pmcid: 3973718
Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). “CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia,” (in eng). Cell Stem Cell, 17(4), 412–421. https://doi.org/10.1016/j.stem.2015.08.008
doi: 10.1016/j.stem.2015.08.008
pubmed: 26387756
pmcid: 4592469
Gebru, M. T., et al. (2020). Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood, 136(9), 1067–1079. https://doi.org/10.1182/blood.2019003124
doi: 10.1182/blood.2019003124
pubmed: 32396937
pmcid: 7453151
Touzet, L., et al. (2019). “CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells,” (in eng). Cancer Medicine, 8(3), 1279–1288. https://doi.org/10.1002/cam4.2007
doi: 10.1002/cam4.2007
pubmed: 30740913
pmcid: 6434215
Saito, Y., et al. (2010). “Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells," (in eng). Sci Transl Med, 2(17), 17ra9. https://doi.org/10.1126/scitranslmed.3000349
doi: 10.1126/scitranslmed.3000349
pubmed: 20371479
pmcid: 3005290
Riether, C., et al. (2017). “CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia,” (in eng). Journal of Experimental Medicine, 214(2), 359–380. https://doi.org/10.1084/jem.20152008
doi: 10.1084/jem.20152008
pubmed: 28031480
pmcid: 5294846
Taussig, D. C., et al. (2005). “Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia,” (in eng). Blood, 106(13), 4086–4092. https://doi.org/10.1182/blood-2005-03-1072
doi: 10.1182/blood-2005-03-1072
pubmed: 16131573
pmcid: 1895250
Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F., & Dick, J. E. (2006). “Targeting of CD44 eradicates human acute myeloid leukemic stem cells,” (in eng). Nature Medicine, 12(10), 1167–1174. https://doi.org/10.1038/nm1483
doi: 10.1038/nm1483
pubmed: 16998484
Kersten, B., et al. (2016). “CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia,” (in eng). British Journal of Haematology, 173(2), 219–235. https://doi.org/10.1111/bjh.13941
doi: 10.1111/bjh.13941
pubmed: 26814163
Goardon, N., et al. (2011). “Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia,” (in eng). Cancer Cell, 19(1), 138–152. https://doi.org/10.1016/j.ccr.2010.12.012
doi: 10.1016/j.ccr.2010.12.012
pubmed: 21251617
Majeti, R., et al. (2009). “CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells,” (in eng). Cell, 138(2), 286–299. https://doi.org/10.1016/j.cell.2009.05.045
doi: 10.1016/j.cell.2009.05.045
pubmed: 19632179
pmcid: 2726837
Oehler, V. G., et al. (2010). CD52 expression in leukemic stem/progenitor cells. Blood, 116(21), 2743. https://doi.org/10.1182/blood.V116.21.2743.2743
doi: 10.1182/blood.V116.21.2743.2743
de Boer, B., et al. (2018). “Prospective isolation and characterization of genetically and functionally distinct AML subclones,” (in eng). Cancer Cell, 34(4), 674-689.e8. https://doi.org/10.1016/j.ccell.2018.08.014
doi: 10.1016/j.ccell.2018.08.014
pubmed: 30245083
Hosen, N., et al. (2007). “CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia,” (in eng). Proc Natl Acad Sci U S A, 104(26), 11008–11013. https://doi.org/10.1073/pnas.0704271104
doi: 10.1073/pnas.0704271104
pubmed: 17576927
pmcid: 1904175
Chung, S. S. et al. (2017). "CD99 is a therapeutic target on disease stem cells in myeloid malignancies," (in eng). Science Translational Medicine, 9(374). https://doi.org/10.1126/scitranslmed.aaj2025 .
Jordan, C. T., et al. (2000). “The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells,” (in eng). Leukemia, 14(10), 1777–1784. https://doi.org/10.1038/sj.leu.2401903
doi: 10.1038/sj.leu.2401903
pubmed: 11021753
Ho, J. M., et al. (2020). “CD200 expression marks leukemia stem cells in human AML,” (in eng). Blood Advances, 4(21), 5402–5413. https://doi.org/10.1182/bloodadvances.2020001802
doi: 10.1182/bloodadvances.2020001802
pubmed: 33147339
pmcid: 7656934
Jan, M., et al. (2011). “Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker,” (in eng). Proc Natl Acad Sci U S A, 108(12), 5009–5014. https://doi.org/10.1073/pnas.1100551108
doi: 10.1073/pnas.1100551108
pubmed: 21383193
pmcid: 3064328
Kikushige, Y., et al. (2010). “TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells,” (in eng). Cell Stem Cell, 7(6), 708–717. https://doi.org/10.1016/j.stem.2010.11.014
doi: 10.1016/j.stem.2010.11.014
pubmed: 21112565
van Rhenen, A., et al. (2007). “The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells,” (in eng). Blood, 110(7), 2659–2666. https://doi.org/10.1182/blood-2007-03-083048
doi: 10.1182/blood-2007-03-083048
pubmed: 17609428
Pabst, C., et al. (2016). “GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo,” (in eng). Blood, 127(16), 2018–2027. https://doi.org/10.1182/blood-2015-11-683649
doi: 10.1182/blood-2015-11-683649
pubmed: 26834243
Barreyro, L., et al. (2012). “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS,” (in eng). Blood, 120(6), 1290–1298. https://doi.org/10.1182/blood-2012-01-404699
doi: 10.1182/blood-2012-01-404699
pubmed: 22723552
pmcid: 3418722
Ågerstam, H., et al. (2015). “Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia,” (in eng). Proc Natl Acad Sci U S A, 112(34), 10786–10791. https://doi.org/10.1073/pnas.1422749112
doi: 10.1073/pnas.1422749112
pubmed: 26261316
pmcid: 4553807
Askmyr, M., et al. (2013). “Selective killing of candidate AML stem cells by antibody targeting of IL1RAP,” (in eng). Blood, 121(18), 3709–3713. https://doi.org/10.1182/blood-2012-09-458935
doi: 10.1182/blood-2012-09-458935
pubmed: 23479569
Eppert, K., et al. (2011). “Stem cell gene expression programs influence clinical outcome in human leukemia,” (in eng). Nature Medicine, 17(9), 1086–1093. https://doi.org/10.1038/nm.2415
doi: 10.1038/nm.2415
pubmed: 21873988
Hogan, C. J., Shpall, E. J., & Keller, G. (2002). “Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice,” (in eng). Proc Natl Acad Sci U S A, 99(1), 413–418. https://doi.org/10.1073/pnas.012336799
doi: 10.1073/pnas.012336799
pubmed: 11782553
pmcid: 117574
Bakker, A. B., et al. (2004). “C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia,” (in eng). Cancer Research, 64(22), 8443–8450. https://doi.org/10.1158/0008-5472.can-04-1659
doi: 10.1158/0008-5472.can-04-1659
pubmed: 15548716
Zeijlemaker, W., et al. (2019). CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia, 33(5), 1102–1112. https://doi.org/10.1038/s41375-018-0326-3
doi: 10.1038/s41375-018-0326-3
pubmed: 30542144
Falini, B., et al. (2005). Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.[see comment][erratum appears in N Engl J Med. 2005 Feb 17;352(7):740]. New England Journal of Medicine, 352(3), 254–266.
doi: 10.1056/NEJMoa041974
pubmed: 15659725
Warburg, O. (1956). “On the origin of cancer cells,” (in eng). Science, 123(3191), 309–314. https://doi.org/10.1126/science.123.3191.309
doi: 10.1126/science.123.3191.309
pubmed: 13298683
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. https://doi.org/10.1126/science.1160809
doi: 10.1126/science.1160809
pubmed: 19460998
pmcid: 2849637
Elstrom, R. L., et al. (2004). “Akt stimulates aerobic glycolysis in cancer cells,” (in eng). Cancer Research, 64(11), 3892–3899. https://doi.org/10.1158/0008-5472.can-03-2904
doi: 10.1158/0008-5472.can-03-2904
pubmed: 15172999
Gottschalk, S., Anderson, N., Hainz, C., Eckhardt, S. G., & Serkova, N. J. (2004). “Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells,” (in eng). Clinical Cancer Research, 10(19), 6661–6668. https://doi.org/10.1158/1078-0432.ccr-04-0039
doi: 10.1158/1078-0432.ccr-04-0039
pubmed: 15475456
Ye, H., et al. (2018). “Subversion of systemic glucose metabolism as a mechanism to support the growth of leukemia cells,” (in eng). Cancer Cell, 34(4), 659-673.e6. https://doi.org/10.1016/j.ccell.2018.08.016
doi: 10.1016/j.ccell.2018.08.016
pubmed: 30270124
pmcid: 6177322
Kobayashi, C. I., & Suda, T. (2012). “Regulation of reactive oxygen species in stem cells and cancer stem cells,” (in eng). Journal of Cellular Physiology, 227(2), 421–430. https://doi.org/10.1002/jcp.22764
doi: 10.1002/jcp.22764
pubmed: 21448925
Janiszewska, M., et al. (2012). “Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells,” (in eng). Genes & Development, 26(17), 1926–1944. https://doi.org/10.1101/gad.188292.112
doi: 10.1101/gad.188292.112
Lagadinou, E. D., et al. (2013). “BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells,” (in eng). Cell Stem Cell, 12(3), 329–341. https://doi.org/10.1016/j.stem.2012.12.013
doi: 10.1016/j.stem.2012.12.013
pubmed: 23333149
pmcid: 3595363
Diehn, M., et al. (2009). “Association of reactive oxygen species levels and radioresistance in cancer stem cells,” (in eng). Nature, 458(7239), 780–783. https://doi.org/10.1038/nature07733
doi: 10.1038/nature07733
pubmed: 19194462
pmcid: 2778612
Chen, Z. X., & Pervaiz, S. (2007). “Bcl-2 induces pro-oxidant state by engaging mitochondrial respiration in tumor cells,” (in eng). Cell Death and Differentiation, 14(9), 1617–1627. https://doi.org/10.1038/sj.cdd.4402165
doi: 10.1038/sj.cdd.4402165
pubmed: 17510660
DiNardo, C. D., et al. (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: A non-randomised, open-label, phase 1b study. The lancet Oncology, 19(2), 216–228. https://doi.org/10.1016/S1470-2045(18)30010-X
doi: 10.1016/S1470-2045(18)30010-X
pubmed: 29339097
Pollyea, D. A., et al. (2018). Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nature Medicine, 24(12), 1859–1866. https://doi.org/10.1038/s41591-018-0233-1
doi: 10.1038/s41591-018-0233-1
pubmed: 30420752
pmcid: 7001730
DiNardo, C. D., et al. (2018). “Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies,” (in eng). American Journal of Hematology, 93(3), 401–407. https://doi.org/10.1002/ajh.25000
doi: 10.1002/ajh.25000
pubmed: 29218851
Jones, C. L., et al. (2018). “Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells,” (in eng). Cancer Cell, 34(5), 724-740.e4. https://doi.org/10.1016/j.ccell.2018.10.005
doi: 10.1016/j.ccell.2018.10.005
pubmed: 30423294
pmcid: 6280965
Jones, C. L., et al. (2020). “Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells,” (in eng). Cell Stem Cell, 27(5), 748-764.e4. https://doi.org/10.1016/j.stem.2020.07.021
doi: 10.1016/j.stem.2020.07.021
pubmed: 32822582
pmcid: 7655603
Hilton, J. (1984). Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Research, 44(11), 5156–60. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/6488175 .
Tsukamoto, N., Chen, J., & Yoshida, A. (1998). Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells, Molecules, & Diseases, 24(2), 231–238. https://doi.org/10.1006/bcmd.1998.0188
doi: 10.1006/bcmd.1998.0188
Corti, S., et al. (2006). Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells, 24(4), 975–985. https://doi.org/10.1634/stemcells.2005-0217
doi: 10.1634/stemcells.2005-0217
pubmed: 16293577
Ma, S., et al. (2008). Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Molecular Cancer Research, 6(7), 1146–1153. https://doi.org/10.1158/1541-7786.MCR-08-0035
doi: 10.1158/1541-7786.MCR-08-0035
pubmed: 18644979
Morimoto, K., et al. (2009). Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Science, 100(6), 1062–1068. https://doi.org/10.1111/j.1349-7006.2009.01151.x
doi: 10.1111/j.1349-7006.2009.01151.x
pubmed: 19385968
Jiang, F., et al. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Molecular Cancer Research, 7(3), 330–338. https://doi.org/10.1158/1541-7786.MCR-08-0393
doi: 10.1158/1541-7786.MCR-08-0393
pubmed: 19276181
Cheung, A. M., et al. (2007). Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia, 21(7), 1423–1430. https://doi.org/10.1038/sj.leu.2404721
doi: 10.1038/sj.leu.2404721
pubmed: 17476279
Schuurhuis, G. J., et al. (2013). Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS ONE, 8(11), e78897. https://doi.org/10.1371/journal.pone.0078897
doi: 10.1371/journal.pone.0078897
pubmed: 24244383
pmcid: 3823975
Hoang, V. T., et al. (2015). The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. International Journal of Cancer, 137(3), 525–536. https://doi.org/10.1002/ijc.29410
doi: 10.1002/ijc.29410
pubmed: 25545165
pmcid: 4755039
Smith, C., Gasparetto, M., Humphries, K., Pollyea, D. A., Vasiliou, V., & Jordan, C. T. (2014). “Aldehyde dehydrogenases in acute myeloid leukemia,” (in eng). Annals of the New York Academy of Sciences, 1310, 58–68. https://doi.org/10.1111/nyas.12414
doi: 10.1111/nyas.12414
pubmed: 24641679
Venton, G., et al. (2016). “Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors,” (in eng). Blood Cancer J, 6(9), e469. https://doi.org/10.1038/bcj.2016.78
doi: 10.1038/bcj.2016.78
pubmed: 27611922
pmcid: 5056970
Annageldiyev, C., et al. (2019). The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. Haematologica, 13, 485. https://doi.org/10.3324/haematol.2018.212886
doi: 10.3324/haematol.2018.212886
Broccoli, D., Young, J. W., & De Lange, T. (1995). Telomerase activity in normal and malignant hematopoietic cells. Proceedings of the National academy of Sciences of the United States of America, 92, 9082–9086.
doi: 10.1073/pnas.92.20.9082
pubmed: 7568077
pmcid: 40928
Watts, J. M., et al. (2016). Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia Research, 49, 62–65. https://doi.org/10.1016/j.leukres.2016.07.013
doi: 10.1016/j.leukres.2016.07.013
pubmed: 27568819
pmcid: 5526052
Williams, J., et al. (2017). Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology, 178(2), 240–249. https://doi.org/10.1111/bjh.14666
doi: 10.1111/bjh.14666
pubmed: 28486748
Lansdorp, P. M. (2017). Maintenance of telomere length in AML. Blood Advances, 1(25), 2467–2472. https://doi.org/10.1182/bloodadvances.2017012112
doi: 10.1182/bloodadvances.2017012112
pubmed: 29296896
pmcid: 5729630
Ly, M., et al. (2019). Diminished AHR signaling drives human acute myeloid leukemia stem cell maintenance. Cancer Research, 79(22), 5799–5811. https://doi.org/10.1158/0008-5472.CAN-19-0274
doi: 10.1158/0008-5472.CAN-19-0274
pubmed: 31519687
Pabst, C., et al. (2014). Identification of small molecules that support human leukemia stem cell activity ex vivo. Nature Methods, 11(4), 436–442. https://doi.org/10.1038/nmeth.2847
doi: 10.1038/nmeth.2847
pubmed: 24562423
Walter, R. B., et al. (2014). Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia, 28(10), 1969–1977. https://doi.org/10.1038/leu.2014.107
doi: 10.1038/leu.2014.107
pubmed: 24721792
pmcid: 4167978
Ng, S. W., et al. (2016). A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature, 540(7633), 433–437. https://doi.org/10.1038/nature20598
doi: 10.1038/nature20598
pubmed: 27926740
Pinho, S., & Frenette, P. S. (2019). Haematopoietic stem cell activity and interactions with the niche. Nature Reviews Molecular Cell Biology, 20(5), 303–320. https://doi.org/10.1038/s41580-019-0103-9
doi: 10.1038/s41580-019-0103-9
pubmed: 30745579
pmcid: 6483843
Villatoro, A., Konieczny, J., Cuminetti, V., & Arranz, L. (2020). Leukemia stem cell release from the stem cell niche to treat acute myeloid leukemia. Front Cell Dev Biol, 8, 607. https://doi.org/10.3389/fcell.2020.00607
doi: 10.3389/fcell.2020.00607
pubmed: 32754595
pmcid: 7367216
Nervi, B., et al. (2009). Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood, 113(24), 6206–6214. https://doi.org/10.1182/blood-2008-06-162123
doi: 10.1182/blood-2008-06-162123
pubmed: 19050309
pmcid: 2699239
Sievers, E. L., et al. (2001). Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19(13), 3244–3254.
doi: 10.1200/JCO.2001.19.13.3244
pubmed: 11432892
Hauswirth, A. W., et al. (2007). Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. European Journal of Clinical Investigation, 37(1), 73–82.
doi: 10.1111/j.1365-2362.2007.01746.x
pubmed: 17181570
Wadleigh, M., et al. (2003). Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.[see comment]. Blood, 102(5), 1578–1582.
doi: 10.1182/blood-2003-01-0255
pubmed: 12738663
Petersdorf, S. H., et al. (2013). “A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia,” (in eng). Blood, 121(24), 4854–4860. https://doi.org/10.1182/blood-2013-01-466706
doi: 10.1182/blood-2013-01-466706
pubmed: 23591789
pmcid: 3682338
Kim, M. Y., et al. (2018). “Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia,” (in eng). Cell, 173(6), 1439-1453.e19. https://doi.org/10.1016/j.cell.2018.05.013
doi: 10.1016/j.cell.2018.05.013
pubmed: 29856956
pmcid: 6003425
Jin, L., et al. (2009). “Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells,” (in eng). Cell Stem Cell, 5(1), 31–42. https://doi.org/10.1016/j.stem.2009.04.018
doi: 10.1016/j.stem.2009.04.018
pubmed: 19570512
Kubasch, A. S., et al. (2020). Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia, 34(4), 1182–1186.
doi: 10.1038/s41375-019-0645-z
pubmed: 31796915
Montesinos, P., et al. (2021). “Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2/3 study,” (in eng). Leukemia, 35(1), 62–74. https://doi.org/10.1038/s41375-020-0773-5
doi: 10.1038/s41375-020-0773-5
pubmed: 32203138
Liu, J., et al. (2015). “Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential,” (in eng). PLoS ONE, 10(9), e0137345. https://doi.org/10.1371/journal.pone.0137345
doi: 10.1371/journal.pone.0137345
pubmed: 26390038
pmcid: 4577081
Pang, W. W., et al. (2013). “Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes,” (in eng). Proc Natl Acad Sci U S A, 110(8), 3011–3016. https://doi.org/10.1073/pnas.1222861110
doi: 10.1073/pnas.1222861110
pubmed: 23388639
pmcid: 3581956
Chao, M. P., et al. (2019). “Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies,” (in eng). Frontiers in Oncology, 9, 1380. https://doi.org/10.3389/fonc.2019.01380
doi: 10.3389/fonc.2019.01380
pubmed: 32038992
Aslostovar, L., et al. (2018). “A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia,” (in eng). Blood Advances, 2(15), 1935–1945. https://doi.org/10.1182/bloodadvances.2018015677
doi: 10.1182/bloodadvances.2018015677
pubmed: 30093531
pmcid: 6093733
Yanagisawa, B., et al. (2020). Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. Leukemia Research, 99, 106477. https://doi.org/10.1016/j.leukres.2020.106477
doi: 10.1016/j.leukres.2020.106477
pubmed: 33220589
pmcid: 7969493
Amatangelo, M. D., et al. (2017). Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood, 130(6), 732–741. https://doi.org/10.1182/blood-2017-04-779447
doi: 10.1182/blood-2017-04-779447
pubmed: 28588019
pmcid: 5553578
Popovici-Muller, J., et al. (2018). Discovery of AG-120 (Ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Medicinal Chemistry Letters, 9(4), 300–305. https://doi.org/10.1021/acsmedchemlett.7b00421
doi: 10.1021/acsmedchemlett.7b00421
pubmed: 29670690
pmcid: 5900343